Houston, TX, United States of America

Fernanda Staquicini

USPTO Granted Patents = 1 

Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 2013

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Fernanda Staquicini: Innovator in Cancer Therapeutics

Introduction

Fernanda Staquicini is a prominent inventor based in Houston, Texas. She has made significant contributions to the field of cancer therapeutics, particularly through her innovative work on MUC18 targeting peptides. Her research aims to improve treatment options for patients suffering from melanoma and leukemia.

Latest Patents

Fernanda holds 1 patent for her invention related to MUC18 targeting peptides. These peptides are designed to therapeutically target B-I lymphocytes, thereby reducing their influence on the metastatic potential of melanoma cells. Additionally, they can be utilized to target cancerous cells, including specific melanoma and leukemia cells. The MUC18 targeting peptides may be incorporated into various constructs, such as fusion constructs, imaging constructs, and therapeutic constructs, which can be used for diagnosing or treating cancer.

Career Highlights

Fernanda is affiliated with the University of Texas System, where she continues her research and development in cancer therapeutics. Her work has garnered attention for its potential to revolutionize treatment methodologies in oncology.

Collaborations

Fernanda collaborates with esteemed colleagues, including Renata Pasqualini and Wadih Arap, who contribute to her research endeavors and enhance the impact of her innovations.

Conclusion

Fernanda Staquicini is a trailblazer in the field of cancer research, with her MUC18 targeting peptides offering promising avenues for therapeutic intervention. Her contributions are vital in the ongoing fight against cancer, showcasing the importance of innovation in medical science.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…